SynthesisPloS one2015

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.

Mayer N Fishman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.